EPO Promotes Bone Repair through Enhanced Cartilaginous Callus Formation and Angiogenesis
Open Access
- 8 July 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (7) , e102010
Abstract
Erythropoietin (EPO)/erythropoietin receptor (EPOR) signaling is involved in the development and regeneration of several non-hematopoietic tissues including the skeleton. EPO is identified as a downstream target of the hypoxia inducible factor-α (HIF-α) pathway. It is shown that EPO exerts a positive role in bone repair, however, the underlying cellular and molecular mechanisms remain unclear. In the present study we show that EPO and EPOR are expressed in the proliferating, pre-hypertrophic and hypertrophic zone of the developing mouse growth plates as well as in the cartilaginous callus of the healing bone. The proliferation rate of chondrocytes is increased under EPO treatment, while this effect is decreased following siRNA mediated knockdown of EPOR in chondrocytes. EPO treatment increases biosynthesis of proteoglycan, accompanied by up-regulation of chondrogenic marker genes including SOX9, SOX5, SOX6, collagen type 2, and aggrecan. The effects are inhibited by knockdown of EPOR. Blockage of the endogenous EPO in chondrocytes also impaired the chondrogenic differentiation. In addition, EPO promotes metatarsal endothelial sprouting in vitro. This coincides with the in vivo data that local delivery of EPO increases vascularity at the mid-stage of bone healing (day 14). In a mouse femoral fracture model, EPO promotes cartilaginous callus formation at days 7 and 14, and enhances bone healing at day 28 indexed by improved X-ray score and micro-CT analysis of microstructure of new bone regenerates, which results in improved biomechanical properties. Our results indicate that EPO enhances chondrogenic and angiogenic responses during bone repair. EPO's function on chondrocyte proliferation and differentiation is at least partially mediated by its receptor EPOR. EPO may serve as a therapeutic agent to facilitate skeletal regeneration.Keywords
This publication has 60 references indexed in Scilit:
- Diabetes-related impairment in bone strength is established early in the life courseWorld Journal of Diabetes, 2013
- Human Early Fracture Hematoma Is Characterized by Inflammation and HypoxiaClinical Orthopaedics and Related Research, 2011
- Unraveling the transcriptional regulatory machinery in chondrogenesisJournal of Bone and Mineral Metabolism, 2011
- Erythropoietin Couples Hematopoiesis with Bone FormationPLOS ONE, 2010
- Role of HIF‐1α in skeletal developmentAnnals of the New York Academy of Sciences, 2010
- Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association studyThe Lancet, 2008
- Activation of the hypoxia-inducible factor-1α pathway accelerates bone regenerationProceedings of the National Academy of Sciences, 2008
- The Relation Between Sox9, TGF-β1, and Proteoglycan in Human Intervertebral Disc CellsJournal of Korean Neurosurgical Society, 2008
- The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal developmentJournal of Clinical Investigation, 2007
- Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promiseKidney International, 2006